- Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families. Glaser, K.B., Li, J., Marcotte, P.A., Magoc, T.J., Guo, J., Reuter, D.R., Tapang, P., Wei, R.Q., Pease, L.J., Bui, M.H., Chen, Z., Frey, R.R., Johnson, E.F., Osterling, D.J., Olson, A.M., Bouska, J.J., Luo, Y., Curtin, M.L., Donawho, C.K., Michaelides, M.R., Tse, C., Davidsen, S.K., Albert, D.H. J. Pharmacol. Exp. Ther. (2012)